Andriy Rusyn
7 Papers
60 Citations
Andriy Rusyn is an academic researcher. The author has contributed to research in topics: Trastuzumab & Epirubicin. The author has an hindex of 5, co-authored 6 publications.
Chat about Author
Papers
FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma
Salah-Eddin Al-Batran,Martin Schuler,Zanete Zvirbule,Georgiy Manikhas,Florian Lordick,Andriy Rusyn,Yuriy Vynnyk,Ihor Vynnychenko,Natalia Fadeeva,Marina Nechaeva,Assen Dudov,Evgeny Gotovkin,Alexander Pecheniy,Igor Bazin,Igor Bondarenko,Bohuslav Melichar,Christian Mueller,Christoph Huber,Ö. Türeci,Ugur Sahin +19 more
TL;DR: IMAB362 is a chimeric monoclonal antibody that mediates specific killing of CLDN18.2-positive cancer cells by activation of immune effector mechanisms and has demonstrated single-agent activity and was safe and tolerable in patients with pretreated gastric cancer.
55
Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma: Updated results from the FAST trial.
Ugur Sahin,Özlem Türeci,Georgy M. Manikhas,Florian Lordick,Andriy Rusyn,Ihor Vynnychenko,Assen Dudov,Igor Bazin,Igor Bondarenko,Bohuslav Melichar,Karl Dhaene,Kai Wiechen,Daniel Maurus,Martin Schuler,Salah-Eddin Al-Batran +14 more
TL;DR: Addition of zolbetuximab to first-line chemotherapy resulted in significantly longer PFS and OS and higher ORR with manageable toxicity and most AEs considered related to zol Betoximab and EOX were of grade ≤ 2 severity; there was no significant increase in grade ≥ 3 events.
22
Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC).
Justin Stebbing,Yauheni Valerievich Baranau,V. Baryash,Alexey Manikhas,Vladimir Moiseyenko,Giorgi Dzagnidze,Edvard Javrid,Dmytro Boliukh,Daniil Stroyakovskiy,Joanna Pikiel,Alexandru Eniu,Dmitry Komov,Zakaria Zautashvili,Gabriela Morar-Bolba,Rubi Khaw Li,Igor Lifirenko,Andriy Rusyn,Sang Joon Lee,Sung Young Lee,Francisco J. Esteva +19 more
TL;DR: The similarity of C and trastuzumab in efficacy and safety for HER2+ EBC was similar and the 95% CIs for the risk ratio estimate were within the equivalence margin.
14
Expression of Claudin 18.2 and HER2 in gastric, gastroesophageal junction, and esophageal cancers: Results from the FAST study.
Martin Schuler,Salah-Eddin Al-Batran,Zanete Zvirbule,Georgy M. Manikhas,Florian Lordick,Andriy Rusyn,Ihor Vynnychenko,Assen Dudov,Igor Bazin,Bohuslav Melichar,Karl Dhaene,Kai Wiechen,Daniel Maurus,Özlem Türeci,Ugur Sahin +14 more
TL;DR: Clin 18.2 (CLDN18.2), a gastric mucosa tight junction protein, is aberrantly expressed in various cancers and in the FAST Phase 2 trial (NCT01630083), IMAB362, an anti-CLDN16.2 mono...
9
EXPRESSION PATTERN OF miR-125b-2, -155, -221, AND -320a IS ASSOCIATED WITH RESPONSE OF BREAST CANCER PATIENTS TO TAMOXIFEN.
O. Pridko,T V Borikun,O. Rossylna,M V Rishko,Andriy Rusyn +4 more
TL;DR: In this article , the authors investigated the correlation between miR-125b-2, -155, -221, and -320a expression in tumor tissue and HER2/neu status and response to tamoxifen treatment in BC patients.
3